White Paper: From Fed-Batch to Perfusion: Unlocking ROI in mAb Manufacturing with Process Intensification
In this white paper, we explore how perfusion-based upstream process intensification using XCell® ATF System can drive cost reductions, increase space-time yield, and deliver strong return on investment.
Key Takeaways:
- Up to 24% lower cost per gram at commercial scale
- 5–10X higher volumetric productivity (space-time-yield)
- Smaller, more flexible facilities with reduced CAPEX and OPEX
- Improved product quality through stable culture conditions
Fill out the form to access the white paper.